Molecular bases of pathological growth

Journal of Endocrine Genetics

Volumn 1, Issue 4, 2000, Pages 179-210

  Argente, J ^a   Perez Jurado, L A ^a   Sotos, J F ^a  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

Author keywords

Genes; Overgrowth; Short stature; Skeletal dysplasias

Indexed keywords

GROWTH HORMONE;

BONE DYSPLASIA; GENE; GENE CLUSTER; GENETIC DISORDER; GIGANTISM; GROWTH; GROWTH DISORDER; GROWTH RETARDATION; HUMAN; METABOLIC DISORDER; MOLECULAR BIOLOGY; MUTATION; REVIEW; SHORT STATURE;

EID: 0033815773     PISSN: 1565012X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (207)

1. Inherited defects in growth hormone synthesis and action
2. The human growth hormone locus: Nucleotide sequence, biology and evolution
3. The human growth hormone gene locus: Structure, evolution and allelic variations
4. Definitive assignment of the growth hormone releasing factor gene to 20q11.2
5. Structure and expression of growth hormone-releasing hormone (GHRH) genes
6. Exclusion of growth hormone-releasing hormone gene mutations in familial isolated growth hormone deficiency by linkage and single strand conformation analysis
7. Polymorphic human somatostatin gene is located on chromosome 3
8. Processing of prosomatostatin
9. Molecular cloning and expression of a pituitary-specific receptor for the growth hormone-releasing hormone
10. Assignment of the human growth hormone-releasing hormone receptor gene (GHRHR) to 7p14 by in situ hybridization
11. Molecular basis of the little mouse phenotype and implications for cell type-specific growth
12. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse
13. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein
14. A tissue-specific transcription factor containing a homeodomain specifies a pituitary phenotype
15. Characterization of the gene encoding human pituitary-specific transcription factor, Pit-I
16. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism
17. Analysis of the human LHX3 neuro-endocrine transcription factor gene and mapping to the subtelomeric region of chromosome 9
18. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency
19. Specification of pituitary cell lineages by the LIM homeobox gene Lhx3
20. Prevalence of human growth hormone-1 gene deletions among patients with isolated growth hormone deficiency from different populations
21. Heterogeneous growth hormone (GH) gene mutations in familial GH deficiency
22. Severe isolated growth hormone deficiency: Heterozygous donor splice site mutation of the GH-1 gene with skipping of the third exon
23. Mutations at intron 3 of the growth hormone (GH)-1 gene cause autosomal dominant isolated GH deficiency
24. A novel mechanism of aberrant pre-mRNA splicing in humans
25. Characterization of an intron splice enhancer that regulates alternative splicing of human GH pre-mRNA
26. X-linked hypogammaglobulinemia and isolated growth hormone deficiency
27. Molecular analysis of X-linked agammaglobulinemia with growth hormone deficiency
28. Suppression of immune function in growth hormone deficient children during treatment with human growth hormone
29. Chromosomal localization of (a) pseudoautosomal growth gene(s)
30. An exon-skipping mutation in the btk gene of a patient with X-linked agamma-globulinemia and isolated growth hormone deficiency
31. A novel single basepair insertion in exon 6 of the Bruton's tyrosine kinase (Btk) gene from a Japanese X-linked agammaglobulinemia patient with growth hormone insufficiency
32. Growth hormone deficiency and empty sella syndrome in a boy with dup(X)(q13.3-q21.2)
33. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia
34. Cretinism with combined hormone deficiency caused by a mutation in the Pit-1 gene
35. A novel E250X mutation of the PIT1 gene in a patient with combined pituitary hormone deficiency
36. A mutation in the POU-homeo-domain of Pit-1 responsible for combined pituitary hormone deficiency
37. Monoallelic expression of normal mRNA in the PIT1 mutation heterozygotes with normal phenotype and biallelic expression in the abnormal phenotype
38. Mutations in PROP1 cause familial combined pituitary hormone deficiency
39. The Prop1 2-base pair deletion is a common cause of combined pituitary hormone deficiency
40. Holoprosencephaly due to mutations in ZIC2, a homologue of drosophila odd-paired
41. Mutations in the human Sonic Hedgehog gene cause holoprosencephaly
42. Autosomal transmission of isolated GH deficiency in iris-dental dysplasia
43. Cloning and characterization of a novel bicoid-related homeo-box transcription factor gene, RIEG, involved in Rieger syndrome
44. A second locus for Rieger syndrome maps to chromosome 13q14
45. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse
46. Physical mapping of the split hand/split foot locus on chromosome 7 and implication in syndromic ectro-dactyly
47. Syndromic ectrodactyly with severe limb, ectodermal, urogenital, and palatal defects maps to chromosome 19
48. Evidence for at least eight Fanconi anemia genes
49. Complementations groups: One or more per gene?
50. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA
51. Cloning of cDNAs for Fanconi's anaemia by functional complementation
52. The Fanconi anaemia group G gene FANCG is identical with XRCC9
53. Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p
54. The Bloom's syndrome gene product is homologous to RecQ helicases
55. Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: A putative Rho/Rac guanine nucleotide exchange factor
56. Genetic pituitary dwarfism with high serum concentration of growthhormone. A new inborn error of metabolism?
57. Pituitary dwarfism with high serum levels of growth hormone
58. Defective sulfation factor generation: A possible etiological link in dwarfism
59. Administration of growth hormone to patients with familial dwarfism with high plasma immunoreactive growth hormone. Measurement of sulfation factor, metabolic, and linear growth responses
60. Defect of human growth hormone in the liver of two patients with Laron type dwarfism
61. Growth hormone receptor and serum binding protein: Purification, cloning and expression
62. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron type dwarfism
63. Classification of growth hormone insensitivity syndrome
64. Genetic aspects of pituitary dwarfism due to absence of biological activity of growth hormone
65. Lessons from the genetics of Laron syndrome
66. Prismatic cases: Laron syndrome (primary growth hormone resistance). From patient to laboratory to patient
67. Growth curves for Laron syndrome
68. Chromosome mapping of the growth hormone receptor gene in man and mouse
69. Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase
70. Famine to feast - Growth honnone and prolactin signal transducers
71. Are there direct, non-IGF-l-mediated effects of hGH?
72. The GH receptor and signal transduction
73. Molecular basis of inherited growth hormone resistance in childhood
74. Recurrent nonsense mutations in the growth hormone receptor from patients with Laron dwarfism
75. Nine novel growth hormone receptor gene mutations in patients with Laron syndrome
76. Receptor mutations and haplotypes in growth hormone receptor deficiency: A global survey and identification of the Ecuadorean El80 splice mutation in an oriental Jewish patient
77. Spectrum of growth hormone receptor mutations and associated haplotypes in Laron syndrome
78. Growth hormone insensitivity syndrome due to point deletion and frameshiff in the growth hormone receptor
79. Diverse growth hormone receptor gene mutations in Laron syndrome
80. Mutation creating a new splice site in the growth hormone receptor genes of 37 Ecuadorean patients with Laron syndrome
81. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: Extended phenotypic study in a very large pedigree
82. A homozygous splice site mutation affecting tile intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein
83. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization
84. Amino acid substitutions in the intracellular part of the growth hormone receptor in a patient with the Laron syndrome
85. A dominant-negative mutation of the growth hormone receptor causes familial short stature
86. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein levels caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain
87. Novel compound heterozygous mutations of growth hormone (GH) receptor gene in a patient with GH insensitivity syndrome
88. Mutations of the growth hormone receptor in children with idiopathic short stature
89. Growth hormone receptor mutations in children with idiopathic short stature
90. Four contiguous amino acid substitutions, identified in patients with Laron syndrome, differently affect the binding affinity and intracellular trafficking of the growth hormone receptor
91. Clinical, biochemical, and molecular investigations of a genetic isolate of growth hormone insensitivity (Laron's syndrome)
92. Absence of serum growth hormone binding protein in patients with growth hormone receptor deficiency (Laron dwarfism)
93. Absence of plasma growth hormone-binding protein in Laron-type dwarfism
94. Laron syndrome due to a post-receptor defect: Response to IGF-I treatment
95. Serum GH binding protein activity identifies the heterozygous carriers for Laron type dwarfism
96. Serum growth hormone binding protein in Laron syndrome patients and their relatives
97. Is there heterozygote expression of growth hormone receptor deficiency?
98. Evidence for partial growth hormone insensitivity among patients with idiopathic short stature
99. Mutations of the growth hormone receptor in children with idiopathic short stature
100. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor 1 gene
101. The pgymy
102. Pseudopituitary dwarfism due to resistance to somatomedin: A new syndrome
103. Short stature with normal growth hormone and elevated IGF-I
104. The pseudoautosomal regions of the human sex chromosomes
105. PHOG: A candidate gene for involvement in the short stature of Turner syndrome
106. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome
107. Deletion mapping of stature determinants on the long arm of the Y chromosome
108. Chromosomal localization of a Y specific growth gene(s)
109. Molecular mapping of Yq deletion in a patient with normal stature
110. Molecular studies of an X;Y translocation chromosome in a woman with deletion of the pseudoautosomal region but normal height
111. Second observation of Silver-Russel (sic) syndrome in a carrier of a reciprocal translocation with one breakpoint at site 17q25
112. Uniparental disomy as a mechanism for human genetic disease
113. Uniparental disomy 7 in Silver-Russell syndrome and primordial growth retardation
114. Duplication of 7p12.1-p13, including GRB10 and IGFBP1, in a mother and daughter with features of Silver-Russell syndrome
115. Duplication of 7p11.2-p13, including GRB10, in Silver-Russell syndrome
116. Identification of the Megl/ Grb10 imprinted gene on mouse proximal chromosome 11, a candidate for the Silver-Russell syndrome gene
117. Grb10 interacts differentially with the insulin receptor, insulin-receptor, and epidermal growth Grb10 Src homology 2 (SH2) novel domain located between the pleckstrin homology and SH2 domains
118. International Nomenclature and Classification of the Osteochondrodysplasias (1997). International Working Group on Constitutional Diseases of the Bone
119. Nomenclatura Internacional y Clasificacion de las Osteochondrodisplasias
120. Osteogenesis imperfecta
121. Localization of achondroplasia gene to the distal 2.5 Mb of human chromosome 4p
122. A gene for achondroplasia-hypochondroplasia maps to chromosome 4p
123. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia
124. A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia
125. Hypochondroplasia: A second recurrent mutation of fibroblast growth factor receptor 3 (FGFR3) at nucleotide 1620
126. Thanatophoric dysplasia (types I and II) caused by distinct mutations in the fibroblast growth factor receptor 3
127. Mutations in exon 17B of cartilage oligomeric matrix protein (COMP) cause pseudoachondroplasia
128. Pseudoachondroplasia and multiple epiphyseal dysplasia produced by mutations in the calcium binding domain of cartilage oligomeric matrix protein (COMP)
129. Genetic and biochemical heterogeneity in patients with the rhizomelic form of chondrodysplasia punctata - A complementation study
130. A cluster of sulfatase genes on Xp22.3: Mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy
131. A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia
132. A type X collagen mutation causes Schmid metaphyseal chondrodysplasia
133. The type II collagenopathies: A spectrum of chondrodysplasias
134. Clinical-molecular correlations in the skeletal dysplasias
135. Expression in cartilage of a 7-amino acid deletion in type II collagen from two unrelated individuals with Kniest dysplasia
136. A single amino acid substitution (G103D) in the type II collagen triple helix produces Kniest dysplasia
137. Clinical and molecular genetics of Stickler syndrome
138. Autosomal dominant and recessive osteochondrodysplasias associated with the COL11A2 locus
139. The dyastrophic dysplasia gene encodes a novel sulfate transporter: Positional cloning by fine-structure linkage disequilibrium mapping
140. Atelosteogenesis type II is caused by mutations in the diastrophic dysplasia sulfate transporter gene (DTDST): Evidence for a phenotypic series involving three chondrodysplasias
141. Achondro-genesis type IB is caused by mutations in the diastrophic dysplasia sulfate transporter gene
142. Mutations in a new gene in Ellis-van Creveld syndrome and Weyers acrodental dysostosis
143. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene
144. SHOX mutations in dyschondrosteosis (Leri-Weill syndrome)
145. Sex chromosome aberrations and stature: Deduction of the principal factors involved in the determination of adult height
146. Growth during puberty in the XYY boy
147. The Y specific growth gene(s): How does it promote stature?
148. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome
149. Growth hormone hyper-secretion in a girl with McCune-Albright syndrome: Comparison with controls and response to a dose of long-acting somatostatin analog
150. Gs alpha mutation at codon 201 in pituitary adenoma causing gigantism in a 6-year-old boy with McCune-Albright syndrome
151. Molecular characterization of the Men I tumor suppressor gene in sporadic pituitary tumors
152. Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene
153. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas
154. Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors
155. Positional cloning for multiple endocrine neoplasia-type 1
156. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states
157. Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly
158. Complexe malformatif familial avec hernie ombilicale et macroglossie - Un 'syndrome nouveau'?
159. Insulin-like growth factor 2 and overgrowth: Molecular biology and clinical implications
160. Imprinting IGF2 and H19: Lack of reciprocity in sporadic Beckwith-Wiedemann syndrome
161. Epigenetic modification and uniparental inheritance of H19 in Beckwith-Wiedemann syndrome
162. Paternally inherited duplications of 11p15.5 and Beckwith-Wiedemann syndrome
163. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour
164. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor
165. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome
166. Neonatal hyper-insulinism
167. An autosomal dominant form of familial persistent hyper-insulinemic hypoglycemia of infancy, not linked to the sulfonylurea receptor locus
168. Familial hyperinsulinism with apparent autosomal dominant inheritance: Clinical and genetic differences from the autosomal recessive trait
169. Familial hyperinsulinism caused by an activating glucokinase mutation
170. A syndrome of congenital hyperinsulinism and hyperammonemia
171. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene
172. Somatic deletion of the imprinted 11p15 region in sporadic persistent hyper-insulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy
173. Translocations involving 4p16.3 in three families: Deletion causing the Pitt-Rogers-Danks syndrome and duplication resulting in a new overgrowth syndrome
174. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens
175. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man
176. The defect in Marfan syndrome
177. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene
178. Partial sequence of a candidate gene for the Marfan syndrome
179. Mutation screening of all 65 exons of the fibrillin-1 gene in 60 patients with Marfan syndrome: Report of 12 novel mutations
180. Characterisation of four novel fibrillin-1 (FBN1) mutations in Marfan syndrome
181. Delineation of the Marfan phenotype associated with mutations in exons 23-32 of the FBN1 gene
182. Fibrillin-1 mutations in Marfan syndrome and other type-1 fibrillinopathies
183. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms
184. A mutation in FBN1 disrupts profibrillin processing and results in isolated skeletal features of the Marfan syndrome
185. Mutation in fibrillin-1 and the Marfanoid-craniosynostosis (Shprintzen-Goldberg) syndrome
186. Congenital contractual arachnodactyly. A heritable disorder of connective tissue
187. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes
188. Homocystinuria: A new inborn error of metabolism associated with mental deficiency
189. Biochemistry and molecular genetics of cystathionine beta-synthase deficiency
190. Identification of a splice site mutation in the cystathionine beta-synthase gene resulting in variable and novel splicing defects of pre-mRNA
191. Functional modeling of vitamin responsiveness in yeast: A common pyridoxine-responsive cystathionine beta-synthase mutation in homocystinuria
192. Characterization of five mis-sense mutations in the cystathionine beta-synthase gene from three patients with B6-nonresponsive homo-cystinuria
193. Simultaneous detection and screening of T833C and G919A mutations of the cystathionine beta-synthase gene by single-strand conformational polymorphism
194. Recent insights into neurofibromatosis type 1: Clear genetic progress
195. Neurofibromatosis: Past, present, and future
196. Deletion of the entire NF1 gene causing distinct manifestations in a family
197. Deletions spanning the neurofibromatosis type 1 gene: Implications for genotype-phenotype correlations in neurofibromatosis type 1
198. Familial neurofibromatosis 1 microdeletions: Cosegregation with distinct phenotype and early onset of cutaneous neurofibromata
199. Do NF1 gene deletions result in a characteristic phenotype?
200. Gross deletions of the neurofibromatosis type 1 (NF1) gene are pre-dominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay
201. Heredofamilial syndrome of mesodermal hamartomas, macrocephaly, and pseudopapilledema
202. Bannayan-Riley-Kuvalcaba syndrome
203. Localization of the Bannayan-Riley-Ruvalcaba syndrome gene to chromosome 10q23
204. Germline mutations in PTEN are present in Bannayan-Zonana syndrome
205. Clinicopathologic findings in the Bannayan-Riley-Ruvalcaba syndrome
206. Deletion of PTEN in a patient with Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease
207. Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome